The Tripledemic: AI-Drug Discovery and the Quest for a Pan-Antiviral Drug
The "tripledemic" is a term used to describe the convergence of three different epidemics: respiratory syncytial virus (RSV), flu, and COVID-19.
Davey Smith, MD, MAS, FACP, FIDSA
Lead Clinical Advisor
This convergence is putting strain on healthcare systems and hospitals are struggling to keep up with the increased demand. Current treatments are inadequate and there is a pressing need for a pan-antiviral drug that can combat all three viruses simultaneously.
Model Medicines has discovered a drug called MDL-001 that has shown antiviral activity against SARS-CoV-2 and influenza in pre-clinical trials. Importantly, MDL-001 also has predicted efficacy against RSV and other RNA viruses, making it a potential pan-antiviral drug. This is critical, as the triple threat of RSV, flu, and COVID-19 is a dangerous combination that can lead to serious complications, such as pneumonia.
MDL-001 has a targeted product profile that includes being an efficacious treatment for at least RSV, SARS-CoV-2, and influenza A & B. It can be administered orally and once a day without significant drug-drug interactions, genotoxicity, or liver or kidney toxicity concerns. This makes it an ideal treatment option for the tripledemic and future pandemics.
The severity of the tripledemic cannot be understated. We need a pan-antiviral drug like MDL-001 to protect ourselves and our communities from the triple threat of RSV, flu, and COVID-19. Model Medicines is taking the next step to clinically validate MDL-001. This is an important step towards providing a solution to the tripledemic and preparing for future pandemics. It is time for a new approach to fighting respiratory viruses and MDL-001 could be the key.
